Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Next Previous
Trial Profile

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GTx

    • Most Recent Events

    • 13 Jun 2018 This trail has been completed in Lithuania (end date: 2018-05-18).
    • 25 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 14 Aug 2017 According to a GTx media release, the Company expects to have top-line results in the third quarter of 2017. This trial has completed the first stage of the two stage trial. Since there was insufficient clinical benefit response (CBR) demonstrated among patients enrolled in the first stage of the trial, the Company has determined that the second and final stage of the trial will not continue.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top